{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:10:16Z","timestamp":1786122616153,"version":"build-2736575974"},"reference-count":31,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Cardiovasc Pharmacol Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1177\/10742484261476920","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T09:00:32Z","timestamp":1785834032000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["From Needle to Pill: Oral PCSK9 Inhibition Enters the Lipid-Lowering Armamentarium"],"prefix":"10.1177","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7848-6600","authenticated-orcid":false,"given":"Andrej","family":"Belancic","sequence":"first","affiliation":[{"name":"University of Rijeka"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4878-8146","authenticated-orcid":false,"given":"Josip Andelo","family":"Borovac","sequence":"additional","affiliation":[{"name":"University Hospital of Split (KBC Split)"},{"name":"University of Split School of Medicine (MEFST)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx144"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf190"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001423"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng1161"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054013"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01690-3"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615664"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801174"},{"key":"e_1_3_5_10_2","volume-title":"FDA approves first oral PCSK9 inhibitor to lower LDL cholesterol in adults with high cholesterol [Internet]","author":"US Food and Drug Administration","year":"2026","unstructured":"US Food and Drug Administration. FDA approves first oral PCSK9 inhibitor to lower LDL cholesterol in adults with high cholesterol [Internet]. Silver Spring (MD): FDA; 2026. [cited 2026 Jul 23]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-oral-pcsk9-inhibitor-lower-ldl-cholesterol-adults-high-cholesterol"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61374-X"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv370"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.16951"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.5218"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2514428"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701131"},{"key":"e_1_3_5_17_2","volume-title":"LIPFENDRA (enlicitide) tablets: US prescribing information [Internet]","author":"Merck & Co., Inc","year":"2026","unstructured":"Merck & Co., Inc. LIPFENDRA (enlicitide) tablets: US prescribing information [Internet]. Merck & Co., Inc.; 2026. [cited 2026 Jul 23]. Available from: https:\/\/www.merck.com\/product\/usa\/pi_circulars\/l\/lipfendra\/lipfendra_pi.pdf"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.063372"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.02.018"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511002"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.20620"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2026.03.036"},{"key":"e_1_3_5_23_2","volume-title":"A study of the oral PCSK9 inhibitor enlicitide in participants with cardiovascular disease or at high cardiovascular risk (CORALreef Outcomes)","author":"gov CT","unstructured":"gov CT. A study of the oral PCSK9 inhibitor enlicitide in participants with cardiovascular disease or at high cardiovascular risk (CORALreef Outcomes). National Library of Medicine (US); [cited 2026 Jul 23]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06008756.Identifier:NCT06008756"},{"key":"e_1_3_5_24_2","volume-title":"PCSK9 inhibitors in acute ischemic stroke patients undergoing endovascular therapy (PCSK9-PROVE)","author":"ClinicalTrials.gov","unstructured":"ClinicalTrials.gov. PCSK9 inhibitors in acute ischemic stroke patients undergoing endovascular therapy (PCSK9-PROVE). National Library of Medicine (US). [cited 2026 Jul 23]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07174375.Identifier:NCT07174375"},{"key":"e_1_3_5_25_2","volume-title":"Early aggressive strategy for treatment of lipid-lowering in acute ischemic stroke delivered with endovascular therapy for large artery occlusion (EAST-LDL)","author":"gov CT","unstructured":"gov CT. Early aggressive strategy for treatment of lipid-lowering in acute ischemic stroke delivered with endovascular therapy for large artery occlusion (EAST-LDL). National Library of Medicine (US); [cited 2026 Jul 23]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07002476.Identifier:NCT07002476"},{"key":"e_1_3_5_26_2","volume-title":"PCSK9 inhibitor for intracranial atherosclerotic symptomatic stenosis (PICASSO)","author":"ClinicalTrials.gov","unstructured":"ClinicalTrials.gov. PCSK9 inhibitor for intracranial atherosclerotic symptomatic stenosis (PICASSO). National Library of Medicine (US). [cited 2026 Jul 23]. Available fromy. https:\/\/clinicaltrials.gov\/study\/NCT07119918.Identifier:NCT07119918"},{"key":"e_1_3_5_27_2","volume-title":"PCSK9 inhibitors in the treatment of calcific aortic stenosis (PICASO)","author":"ClinicalTrials.gov","unstructured":"ClinicalTrials.gov. PCSK9 inhibitors in the treatment of calcific aortic stenosis (PICASO). National Library of Medicine (US). [cited 2026 Jul 23]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07256197.Identifier:NCT07256197"},{"key":"e_1_3_5_28_2","volume-title":"A multicenter, prospective, randomized controlled trial to evaluate the efficacy of PCSK-9 inhibitors in delaying the progression of calcified aortic valve disease","author":"gov CT","unstructured":"gov CT. A multicenter, prospective, randomized controlled trial to evaluate the efficacy of PCSK-9 inhibitors in delaying the progression of calcified aortic valve disease. National Library of Medicine (US); [cited 2026 Jul 23]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06996223.Identifier:NCT06996223"},{"key":"e_1_3_5_29_2","volume-title":"Alirocumab for stabilisation of symptomatic vulnerable carotid plaque (CAROTID-STABIL)","author":"gov CT","unstructured":"gov CT. Alirocumab for stabilisation of symptomatic vulnerable carotid plaque (CAROTID-STABIL). National Library of Medicine (US); [cited 2026 Jul 23]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07586540.Identifier:NCT07586540"},{"key":"e_1_3_5_30_2","volume-title":"A study on efficacy and safety of HST101 in Chinese patients with hypercholesterolemia","author":"ClinicalTrials.gov","unstructured":"ClinicalTrials.gov. A study on efficacy and safety of HST101 in Chinese patients with hypercholesterolemia. National Library of Medicine (US). [cited 2026 Jul 23]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06568471.Identifier:NCT06568471"},{"key":"e_1_3_5_31_2","article-title":"A phase III study of AZD0780 on major adverse cardiovascular events in patients with a history of ASCVD events or at high risk for a first event (AZURE-Outcomes)","author":"ClinicalTrials.gov","unstructured":"ClinicalTrials.gov. A phase III study of AZD0780 on major adverse cardiovascular events in patients with a history of ASCVD events or at high risk for a first event (AZURE-Outcomes). National Library of Medicine (US); [cited 2026 Jul 23]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07000357.Identifier:NCT07000357","journal-title":"National Library of Medicine (US)"},{"key":"e_1_3_5_32_2","volume-title":"A study of enlicitide decanoate in children and adolescents with heterozygous familial hypercholesterolemia","author":"gov CT","unstructured":"gov CT. A study of enlicitide decanoate in children and adolescents with heterozygous familial hypercholesterolemia. National Library of Medicine (US); [cited 2026 Jul 23]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07058077.Identifier:NCT07058077"}],"container-title":["Journal of Cardiovascular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10742484261476920","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10742484261476920","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10742484261476920","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T11:23:47Z","timestamp":1786101827000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10742484261476920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":31,"alternative-id":["10.1177\/10742484261476920"],"URL":"https:\/\/doi.org\/10.1177\/10742484261476920","relation":{},"ISSN":["1074-2484","1940-4034"],"issn-type":[{"value":"1074-2484","type":"print"},{"value":"1940-4034","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"article-number":"10742484261476920"}}